Arcus Biosciences, Inc.
HealthcareNYSE:RCUS · New York Stock Exchange
+$0.50 today
Vol 1.23M · Avg 1.29M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-55.9%
avg -36.5%
ROIC
-42.5%
avg -27.2%
ROA
-31.0%
avg -22.0%
Analysis
ROA is currently the strongest return metric at -31.0% versus its period average of -22.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Terry J. Rosen | Co-Founder, Chairman & Chief Executive Officer | $1.45M | — | 66 | $2.24M | 2.22% |
Juan Carlos Jaen | Co- Founder & President | $1.01M | — | 68 | $126,000.00 | 0.13% |
Jennifer A. Jarrett | Advisor | $1.00M | — | 55 | $224,024.00 | 0.22% |
Richard A. Markus | Chief Medical Officer | $933,883.00 | — | — | $96,000.00 | 0.10% |
Robert C. Goeltz | Principal Financial Officer & Chief Financial Officer | $792,694.00 | — | 53 | $184,607.00 | 0.18% |
Carolyn C. Tang | General Counsel & Corporate Secretary | $603,200.00 | — | 47 | $184,607.00 | 0.18% |
Holli Kolkey | Vice President of Corporate Communications | — | — | — | — | — |
Alexander Azoy | Chief Accounting Officer | — | — | 50 | $39,581.00 | 0.04% |
Yvonne Gehring | Senior Vice President of Human Resources | — | — | — | — | — |
Pia Eaves | Vice President of Investor Relations & Strategy | — | — | — | — | — |
K. Christopher Garcia | Co-Founder & Member of Scientific Advisory Board | — | — | — | — | — |
Jonathan Yingling | Chief Scientific Officer | — | — | 57 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
38
$11.44M
Net Sentiment
$11.44M
Net selling
Most Active
Jaen Juan C.
14 transactions
1–10 of 38
Analysis
Insiders reported 0 buys worth $0.00 and 38 sells worth $11.44M over the last 12 months. That adds up to net selling of $11.44M. Jaen Juan C. was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +280.8% | +26.4% (10yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +280.8% over three years. Forward estimates point to Revenue at +26.4% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.44B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
89bio, Inc.
ETNB
$2.20B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
Galapagos N.V.
GLPG
$1.84B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
Who manages RCUS?
Arcus Biosciences, Inc. (RCUS) lists 12 active executives. The top listed executive is Jennifer A. Jarrett, Advisor.
Are RCUS insiders buying or selling?
Recent insider activity shows net buying of $399.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.